ALLARITY THERAPEUTICS INC
ALLRNASDAQTrading Snapshot
- Day Range
- $0.96 – $0.97
- 52-Week Range
- $0.77 – $1.84
- Volume
- $3.46B
- Avg Volume
- $4.11B
- Shares Outstanding
- 15.9M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $320,000
- Last Q Revenue
- $74,689
- P/E Ratio
- -1.2
- P/S Ratio
- 44.5x
- EPS (TTM)
- $-0.78
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +96.9%
Why Investors Own ALLR
- ✓High-growth profile — revenue up +17.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALLARITY THERAPEUTICS INC
ALLR
StockOtter · stockotter.spaceAbout ALLARITY THERAPEUTICS INC
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable external partnerships
Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a different
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dua
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR 20
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.